NuCana Plc up on advancing biliary tract cancer study

NuCana

15/09/2021 19:23

** Shares of drug developer  NCNA.O  rise 3.3% to $2.45
    ** Co says it has completed enrollment of patients required
to conduct first interim analysis in ongoing trial of its
experimental cancer therapy
    ** Late-stage study is testing NCNA's Acelarin in patients
with advanced biliary tract cancer, in which malignant cells
form in bile ducts
    ** 418 patients have been enrolled and analysis will be
conducted after 418th patient has completed 28 weeks of
follow-up, which is expected to occur in H1 of 2022 - NCNA
    ** Co says data from first interim analysis may support a
submission for marketing approval in U.S. under FDA's
accelerated approval program

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))